RPL27

Large ribosomal subunit protein eL27 · P61353 · RPL27 on Sugi Atlas →

3,584 patent compounds predicted against RPL27, 1,856 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL5500526	0.41	4/20
SCHEMBL5500532	0.41	4/20
SCHEMBL5503310	0.41	4/20
SCHEMBL11844361	0.35	4/20
SCHEMBL2000440	0.39	3/20
SCHEMBL8219903	0.36	3/20
SCHEMBL11627320	0.34	3/20
SCHEMBL10271044	0.55	2/20
SCHEMBL6394396	0.47	2/20
N-Methylpiperidine (SCHEMBL11205373)	0.42	2/20
Bicarbonate (SCHEMBL9058396)	0.42	2/20
SCHEMBL4960293	0.41	2/20
SCHEMBL4961968	0.40	2/20
SCHEMBL6686992	0.40	2/20
SCHEMBL9429122	0.38	2/20
Chloramphenicol (SCHEMBL10796001)	1.00	1/20
Geneticin (SCHEMBL15596)	0.93	1/20
Geneticin (SCHEMBL5006573)	0.93	1/20
Geneticin (SCHEMBL9920496)	0.93	1/20
Chloramphenicol (SCHEMBL16111)	0.90	1/20

Clinical trials — most relevant to RPL27 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes	PHASE4	UNKNOWN
Predictability Studies on the Efficacy of TNF-α Inhibitors in Chinese RA From Real World	PHASE4	UNKNOWN
COMPARING TWO PROTOCOLS FOR FINAL OOCYTE MATURATION IN POOR RESPONDERS UNDERGOING GnRH-ANTAGONIST ICSI CYCLES	PHASE3	UNKNOWN
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients	PHASE2	COMPLETED
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients	PHASE1/PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Targeting Endoplasmic Reticulum Stress in Human Hypertension	PHASE1/PHASE2	RECRUITING
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer	PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors	PHASE1	COMPLETED
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery	PHASE1	COMPLETED
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors	PHASE1	COMPLETED
Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma	nan	COMPLETED
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
Genetic Variation in TRAF3IP2 (rs13190932)	nan	RECRUITING
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy	nan	UNKNOWN
Impact of Mutations in Aminoacyl tRNA Synthetases on Protein Translation and Cellular Stress	nan	WITHDRAWN
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors	nan	COMPLETED
RibOSE - Glucose and Resistance Exercise Training	nan	COMPLETED
Prevalence of a Non-Expressing 11B Mutation in Aka Peoples of the Central African Republic	nan	COMPLETED
Gene Expression, Metabolomic, Microbiome, and Calcium Metabolism in Response to Varied Vitamin D Dosages	nan	COMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
miR-155 Expression in Episodic and Chronic Migraine	nan	UNKNOWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Lumbar Spine Muscle Degeneration Inhibits Rehabilitation-Induced Muscle Recovery	nan	COMPLETED
Exercise-induced Epigenetic Adaptations	nan	COMPLETED
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
LINC00511/miR-185-3p Axis and miR-301a-3p Markers for Breast Cancer Diagnosis	nan	COMPLETED
Perfusion-Induced Hyperthermia for Metastatic Carcinoma	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a RPL27 binder may also engage these)

Protein	Name	Similarity
Q4R8Z4	—	1.000	Q4R8Z4 →
P61358	—	1.000	P61358 →
P61357	—	1.000	P61357 →
A1XQU5	—	1.000	A1XQU5 →
P61356	—	1.000	P61356 →
P61355	—	1.000	P61355 →
P61354	—	1.000	P61354 →
G1TXF6	—	1.000	G1TXF6 →
Q9XSU7	—	1.000	Q9XSU7 →
Q90YU1	—	1.000	Q90YU1 →
P61359	—	1.000	P61359 →
Q7ZV82	—	0.999	Q7ZV82 →
P0C2H7	—	0.975	P0C2H7 →
P91914	—	0.973	P91914 →
O14388	—	0.971	O14388 →
P0C2H6	—	0.970	P0C2H6 →
O74538	—	0.967	O74538 →
Q9P843	—	0.966	Q9P843 →
P55844	—	0.963	P55844 →
Q43291	—	0.963	Q43291 →
A0A1D8PFG4	—	0.962	A0A1D8PFG4 →
Q9FDZ9	—	0.957	Q9FDZ9 →
Q02984	—	0.953	Q02984 →
Q1JQ99	—	0.948	Q1JQ99 →
Q9SIM4	—	0.947	Q9SIM4 →
Q9XET4	—	0.943	Q9XET4 →
Q949H0	—	0.941	Q949H0 →
Q90YV0	—	0.941	Q90YV0 →
Q9ZNS1	—	0.940	Q9ZNS1 →
P62251	—	0.940	P62251 →